Referral
Subject: Urgent Referral for Evaluation of Neonatal Hyperbilirubinemia and Hemoglobin Decline
Dear Colleague,
I am referring a 10-day-old male neonate for your expert evaluation and management. He was delivered full-term via normal vaginal birth and has recently been admitted due to significant unconjugated hyperbilirubinemia. Concerningly, his initial hemoglobin level of 17 gm/dl has sharply declined to 5.4 gm/dl without any overt clinical signs to explain such a change.
The neonate is stable but the combination of rapid hemoglobin drop and hyperbilirubinemia requires thorough investigation to identify underlying causes and appropriate management strategies.
We appreciate your prompt attention to this referral and look forward to your guidance in managing this complex case.
Thank you for your collaboration.
Reply
Dear Colleague,
Thank you for your referral of the 10-day-old male neonate presenting with jaundice and moderate pallor. Following a comprehensive evaluation, we have identified several key findings and have initiated appropriate investigations to further clarify the underlying etiology of his symptoms.
Clinical Overview:
- Age/Gestation: 10 days old, born at 37 weeks gestation via vaginal delivery.
- Clinical Findings: The neonate exhibits jaundice and moderate pallor but remains hemodynamically stable. Cardiac examination is normal, the chest is clear, and the abdomen is soft and lax without organomegaly.
- Blood Group: Both the neonate and mother are O-negative, which has been considered in our assessment.
Laboratory Findings and Diagnostic Work-up:
- Hematological Assessments: Initial lab results indicate severe normocytic anemia and reticulocytosis, suggesting an active bone marrow response. Unconjugated hyperbilirubinemia and slightly elevated lactate dehydrogenase (LDH) levels were also noted, which could indicate hemolysis.
- Immunohematological Testing: The Direct Coombs test was negative, ruling out autoimmune hemolysis.
- Infectious Disease Screening: Comprehensive screening for common perinatal infections (TORCH) and virology panel including HIV, Hepatitis A, B, C, Parvovirus B19, Varicella, CMV, and EBV returned unremarkable results.
- Metabolic and Enzyme Assays: G6PD and Pyruvate Kinase enzyme levels were assessed to explore potential enzymatic defects leading to hemolysis. G6PD levels were normal; however, Pyruvate Kinase activity was notably reduced.
- Hemoglobin Analysis: Hemoglobin electrophoresis was consistent with the neonatal profile showing elevated fetal hemoglobin (HbF), and the peripheral blood smear revealed polychromatophilia, anisocytosis, and poikilocytosis, which are indicative of a regenerative anemia.
Initial Impression:
Based on our findings, the anemia and associated symptoms appear to be predominantly due to a Pyruvate Kinase deficiency, a hereditary condition leading to chronic nonspherocytic hemolytic anemia. This enzymatic defect impairs the red blood cells’ ability to generate adequate amounts of ATP, making them more susceptible to destruction.
Management Plan
Supportive Care: Close monitoring of hemoglobin levels and bilirubin is essential, especially in the neonatal period. Intervention may include phototherapy for hyperbilirubinemia and potentially transfusions for severe anemia.
Long-term Monitoring: Regular follow-up to monitor growth and development, as well as periodic reassessments of hemoglobin and reticulocyte counts to manage and anticipate hemolytic episodes.
Recommendations:
Family Counseling and Genetic Testing: Given the genetic nature of Pyruvate Kinase deficiency, genetic counseling for the family is recommended, along with testing of parental samples to assess carrier status and provide appropriate genetic advice.
Discussion
Pyruvate kinase (PK) deficiency is a metabolic disorder that leads to a variable degree of chronic non-spherocytic hemolytic anemia. It is recognized as the most common cause of congenital non-spherocytic hemolytic anemia, with an estimated prevalence of 1 in 20,000 in the general white population. This condition presents with a spectrum of clinical manifestations, ranging from severe neonatal jaundice and potentially fatal anemia at birth, to chronic transfusion-dependent hemolysis, and even fully compensated hemolysis without overt anemia. Common clinical findings include chronic icterus, gallstones, and splenomegaly.
Diagnostic Approach: The initial evaluation for suspected PK deficiency typically involves:
- Complete Blood Count (CBC): Helps assess the presence of anemia.
- Differential Blood Count and Reticulocyte Count: Indicate increased red blood cell turnover if elevated.
- Serum Bilirubin Levels: Increased levels suggest hemolysis.
- Peripheral Blood Film: Helps visualize red blood cell morphology and can show normochromic, normocytic, or macrocytic anemia with reticulocytosis, typical in hemolytic disorders.
- Direct Coombs Test: A negative result helps exclude immune-mediated hemolysis.
Laboratory Findings: Patients with PK deficiency often exhibit enzyme activity rates between 5-25% of normal. Measurement of metabolic intermediates like 2,3-diphosphoglycerol and glucose-6-phosphate, which accumulate due to the enzymatic block, can further support the diagnosis.
Additional Findings May Include:
- Bone Marrow Examination: Reveals normoblastic erythroid hyperplasia.
- Extramedullary Hematopoiesis: Presence in sites outside of bone marrow, such as the spleen.
- Organ Changes: Splenic and hepatic hemosiderosis, splenic congestion, reticuloendothelial hyperplasia, erythrophagocytosis, and increased iron stores are commonly observed.
Genetic and Biochemical Basis: PK deficiency is caused by mutations in the PKLR gene, which is crucial for pyruvate kinase enzyme production in the liver and red blood cells. This enzyme plays a pivotal role in glycolysis, the metabolic pathway that breaks down glucose to produce ATP, which is essential for cellular energy.
Mutations in the PKLR gene lead to a reduction in functional pyruvate kinase, resulting in inadequate ATP production. This energy deficit in red blood cells causes their premature destruction in the spleen, a condition exacerbated by the accumulation of intermediate products of glycolysis upstream of the enzymatic block.
Clinical Consequences: The rapid destruction of red blood cells primarily in the spleen leads to hemolytic anemia, characterized by symptoms such as fatigue, pallor, and shortness of breath due to decreased oxygen delivery to tissues. The chronic destruction also contributes to an enlarged spleen.
Management and Follow-Up: Management strategies for PK deficiency focus on treating and preventing the symptoms and complications associated with chronic hemolysis. This may include folic acid supplementation, iron chelation therapy in cases of iron overload, and possibly splenectomy in severe cases to reduce hemolysis. Regular monitoring and supportive care are essential to manage the anemia and prevent complications such as gallstone disease.
In summary, PK deficiency is a complex disorder requiring a comprehensive diagnostic approach and a multidisciplinary management strategy to address the varied clinical manifestations and to improve patient outcomes.
Read More Articles About PK deficiency
Management of pyruvate kinase deficiency in children and adults
Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study
Check the correct answers.
Question-1:
Correct Answer: C) PK deficiency is an autosomal recessive disorder resulting from mutations in the PKLR gene.
Explanation: PK deficiency is caused by mutations in the PKLR gene, which is inherited in an autosomal recessive pattern. This means that an individual must inherit two copies of the mutated gene, one from each parent, to manifest the disease. The PKLR gene encodes the pyruvate kinase enzyme, which is critical for glycolysis, the primary pathway for glucose metabolism in red blood cells.
Question-2:
Correct Answer: B) Elevated levels of 2,3-diphosphoglycerate.
Explanation: In Pyruvate Kinase Deficiency, the block in glycolysis due to insufficient enzyme activity leads to an accumulation of intermediates such as 2,3-diphosphoglycerate (2,3-DPG). This accumulation occurs because the enzyme defect causes a bottleneck, leading to an increase in metabolites upstream of the block. Elevated levels of 2,3-DPG can affect oxygen delivery by red blood cells, as 2,3-DPG lowers the affinity of hemoglobin for oxygen, facilitating oxygen release to tissues. This biochemical feature is characteristic and helps to distinguish PK deficiency from other causes of hemolytic anemia, where such a specific increase in a glycolytic intermediate is not observed.
References
- Zanella A et al, Pyruvate kinase deficiency: the genotype-phenotype association. Blood Rev. 2007 Jul; 21(4):217-31. Epub 2007 Mar 13. Review.
- Andersen FD et al. Unexpectedly high but still asymptomatic iron overload in a patient with pyruvate kinase deficiency. Hematol J. 2004. 5(6):543-5.
Leave a Reply